You are here: Industry Insights > Market News > AZ delivers 1.8m doses ahead of mass rollout

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Vibegron Intermediate CAS:1421271-01-3

Food Grade Fish Collagen

Vibegron Intermediate CAS:1295539-30-8

Vibegron Intermediate CAS:1426235-01-9

Vibegron Intermediate CAS:163625-46-5

Vibegron Intermediate

AZ delivers 1.8m doses ahead of mass rollout

firstwordpharmaJune 07, 2021

Tag: AstraZeneca , COVID-19 , Vaccine

Favorites

Thailand's publish health ministry said AstraZeneca delivered 1.8 million locally produced COVID-19 vaccine doses, the first of 6 million scheduled for delivery this month, reported the Bangkok Post.

AZ delivers 1.8m doses ahead of mass rollout

AstraZeneca said it started receiving deliveries from its authorised producer Siam Bioscience last week.

James Teague, AstraZeneca's country president, said the delivery was significant and marked the start of a sustainable supply of the vaccine in Thailand.

The company would be able to supply the vaccine as scheduled in Thailand, and begin shipments to other Asean countries in July, he said.

Previous:South Korea's IP laws key to expanding COVID-19 vaccine partnership: US senators

Next:Dr Reddy’s recalls 2,980 bottles of Atorvastatin Calcium tablets in US

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

AZ delivers 1.8m doses ahead of mass rollout | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Inactivated Influenza Vaccine(Split Virion) manufactured by Hualan Bio

Qualified Trivalent Influenza Vaccine

Rabies Vaccine(Vero Cell)for Human use

Influenza Vaccine(Split Virion),Inactivated manufactured by Hualan Bio

High-dose trivalent influenza vaccine

Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality

Influenza Vaccine by Hualan Bio

Haemophilus Influenza Type B Conjugate Vaccine

SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Hualan

AZ delivers 1.8m doses ahead of mass rollout

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>